Evolocumab mechanism to reduce LDL cholesterol (WP3408)

Evolocumab (Repatha) is an injectable monoclonal antibody that effectively reduces LDL-Cholesterol levels. A limited quantity of LDL-Cholesterol is extracted from circulative blood when PCSK9-bound LDLR is degraded upon internalization in Liver cells. Evolocumab competitively bind PCSK9 away from LDLR complexes, which allows LDLR to be recycled, returning to the surface and clearing additional molecules of LDL-Cholesterol.
last edited

Authors

Alex Pico , Egon Willighagen , Maintenance bot , Susan Coort , Denise Slenter , Eric Weitz , Marvin Martens , Martina Summer-Kutmon , and Lars Willighagen

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organism

Homo sapiens

Communities

Diseases

Annotations

Pathway Ontology: altered cholesterol biosynthetic pathway altered cholesterol transport pathway drug pathway

Cell Type Ontology: hepatocyte

Participants

Label Type Compact Identifier
LDL-Cholesterol Metabolite chebi:47774
Evolocumab Metabolite wikidata:Q15623825
LDL-Cholesterol Metabolite chebi:47774
LDL-Cholesterol Metabolite chebi:47774
LDL-Cholesterol Metabolite chebi:47774
LDL-Cholesterol Metabolite chebi:47774
PCSK9 GeneProduct ensembl:ENSG00000169174
LDLR GeneProduct ensembl:ENSG00000130164
PCSK9 GeneProduct ensembl:ENSG00000169174
LDLR GeneProduct ensembl:ENSG00000130164
PCSK9 GeneProduct ensembl:ENSG00000169174
LDLR GeneProduct ensembl:ENSG00000130164
LDLR GeneProduct ensembl:ENSG00000130164
LDLR GeneProduct ensembl:ENSG00000130164

References

  1. PCSK9 inhibitors: the next cholesterol-lowering blockbusters? The Pharmaceutical Journal [Internet]. 2015; Available from: http://dx.doi.org/10.1211/PJ.2015.20068181 DOI